( July 27, 2026, 3:31 PM EDT) -- CHARLOTTESVILLE, Va. — A Virginia federal judge held that the U.S. Food and Drug Administration acted arbitrarily and capriciously when it instituted a 2023 risk evaluation and mitigation strategy (REMS) decision that removed the in-person dispensing requirement for the abortion drug mifepristone but added certain pharmacy certifications and other requirements, remanding the decision to the agency for further review....